CompletedNot Applicable

Probiotic S. Salivarius K12 for the Prevention of Upper Respiratory Tract Infection in Nursery-age Children

Pakistan287 participantsStarted 2022-01-05

Plain-language summary

The purpose of this retrospective study is to assess the treatment benefits of probiotic Streptococcus salivarius K12 for the prevention of recurrent bacterial and viral infections of the pharynx, tonsils and ears in children under 3 years of age.

Who can participate

Age range1 Year – 3 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy children attending the 1st or 2nd year of nursery (under aged 3 years) * Treated with probiotic Streptococcus salivarius K12 (1 billion CFU) for 90 continuous days * Children not treated with probiotic Streptococcus salivarius K12 Exclusion Criteria: * Children with underlying health condition

What they're measuring

Incidence of any Gastrointestinal upset

Timeframe: 03 Months

Bacterial or respiratory viral infection

Timeframe: 03 Months

Use of antibiotics or antivirals

Timeframe: 03 Months

Trial details

NCT IDNCT05840926

SponsorLiaquat University of Medical & Health Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-20

View on ClinicalTrials.gov More Upper Respiratory Tract Infection trials